The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Serum Globotriaosylceramide Assay as a Screening Test for Fabry Disease in Patients with ESRD on Maintenance Dialysis in Korea

  • Kim, Jeong-Yup (Division of Nephrology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Hyun, Young-Youl (Division of Nephrology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Lee, Ji-Eun (Division of Nephrology, Department of Internal Medicine, Wonkwang University College of Medicine) ;
  • Yoon, Hye-Ran (Division of Pharmacy, Duksung Women's University) ;
  • Kim, Gu-Hwan (Medical Genetics Clinic & Laboratory, Department of Pediatrics, Asan Medical Center) ;
  • Yoo, Han-Wook (Department of Pediatrics, Ulsan University College of Medicine) ;
  • Cho, Seong-Tae (Western Dialysis Physician Association (WDPA)) ;
  • Chun, No-Won (Western Dialysis Physician Association (WDPA)) ;
  • Jeoung, Byoung-Chunn (Western Dialysis Physician Association (WDPA)) ;
  • Kim, Hwa-Jung (Western Dialysis Physician Association (WDPA)) ;
  • Kim, Keong-Wook (Western Dialysis Physician Association (WDPA)) ;
  • Kim, Seong-Nam (Western Dialysis Physician Association (WDPA)) ;
  • Kim, Yung-A (Western Dialysis Physician Association (WDPA)) ;
  • Lee, Hyun-Ah (Western Dialysis Physician Association (WDPA)) ;
  • Lee, Jong-Young (Western Dialysis Physician Association (WDPA)) ;
  • Lee, Yung-Chun (Western Dialysis Physician Association (WDPA)) ;
  • Lim, Hun-Kwan (Western Dialysis Physician Association (WDPA)) ;
  • Oh, Keong-Sik (Western Dialysis Physician Association (WDPA)) ;
  • Son, Seong-Hwan (Western Dialysis Physician Association (WDPA))
  • Received : 2009.12.10
  • Accepted : 2010.06.22
  • Published : 2010.12.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Fabry disease is an X-linked recessive and progressive disease caused by ${\alpha}$-galactosidase A (${\alpha}$-GaL A) deficiency. We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent patients and the efficacy of serum globotriaosylceramide (GL3) screening. Methods: A total of 480 patients of 1,230 patients among 17 clinics were enrolled. Serum GL3 levels were measured by tandem mass spectrometry. Additionally, we studied the association between increased GL3 levels and cardiovascular disease, cerebrovascular disease, or left ventricular hypertrophy. Results: Twenty-nine patients had elevated serum GL3 levels. The ${\alpha}$-GaL A activity was determined for the 26 patients with high GL3 levels. The mean ${\alpha}$-GaL A activity was 64.6 nmol/hr/mg (reference range, 45 to 85), and no patient was identified with decreased ${\alpha}$-GaL A activity. Among the group with high GL3 levels, 15 women had a ${\alpha}$-GaL A genetics analysis. No point mutations were discovered among the women with high GL3 levels. No correlation was observed between serum GL3 levels and ${\alpha}$-GaL A activity; the Pearson correlation coefficient was 0.01352 (p = 0.9478). No significant correlation was observed between increased GL3 levels and the frequency of cardiovascular disease or cerebrovascular disease. Conclusions: Fabry disease is very rare disease in patients with end-stage renal disease. Serum GL3 measurements as a screening method for Fabry disease showed a high false-positive rate. Thus, serum GL3 levels determined by tandem mass spectrometry may not be useful as a screening method for Fabry disease in patients with end stage renal disease.

Keywords

References

  1. Bekri S, Enica A, Ghafari T, et al. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract 2005;101:c33-c38. https://doi.org/10.1159/000085709
  2. Rodriguez-Mari A, Coll MJ, Chabas A. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum Mutat 2003;22:258.
  3. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-242. https://doi.org/10.1111/j.1365-2362.2004.01309.x
  4. Linthorst GE, Hollak CE, Korevaar JC, Van Manen JG, Aerts JM, Boeschoten EW. alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant 2003;18:1581-1584. https://doi.org/10.1093/ndt/gfg194
  5. Kotanko P, Kramar R, Devrnja D, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004;15:1323-1329. https://doi.org/10.1097/01.ASN.0000124671.61963.1E
  6. Tsakiris D, Simpson HK, Jones EH, et al. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 1996;11 Suppl 7:4-20. https://doi.org/10.1093/ndt/11.1.4
  7. Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002;61:249-255. https://doi.org/10.1046/j.1523-1755.2002.00097.x
  8. Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003;64:801-807. https://doi.org/10.1046/j.1523-1755.2003.00160.x
  9. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-293. https://doi.org/10.1056/NEJM199508033330504
  10. Meroni M, Spisni C, Tazzari S, et al. Isolated glomerular proteinuria as the only clinical manifestation of Fabry's disease in an adult male. Nephrol Dial Transplant 1997;12:221-223. https://doi.org/10.1093/ndt/12.1.221
  11. Brenner BM, Grünfeld JP. Renoprotection by enzyme replacement therapy. Curr Opin Nephrol Hypertens 2004;13:231-241. https://doi.org/10.1097/00041552-200403000-00012
  12. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an underrecognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-346. https://doi.org/10.7326/0003-4819-138-4-200302180-00014
  13. Choi JH, Cho YM, Suh KS, et al. Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease. J Korean Med Sci 2008;23:243-250. https://doi.org/10.3346/jkms.2008.23.2.243
  14. Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007;30:184-192. https://doi.org/10.1007/s10545-007-0521-2
  15. Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004;144(5 Suppl):S20-S26. https://doi.org/10.1016/j.jpeds.2004.01.051
  16. Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikle PJ. Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chem 2004;50:1979-1985. https://doi.org/10.1373/clinchem.2004.037937
  17. Ginzburg L, Kacher Y, Futerman AH. The pathogenesis of glycosphingolipid storage disorders. Semin Cell Dev Biol 2004;15:417-431. https://doi.org/10.1016/j.semcdb.2004.03.003
  18. Pastores GM, Lien YH. Biochemical and molecular genetic basis of Fabry disease. J Am Soc Nephrol 2002;13 Suppl 2:S130-133.
  19. Nelson BC, Roddy T, Araghi S, et al. Globotriaosylceramide isoform profiles in human plasma by liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004;805:127-134. https://doi.org/10.1016/j.jchromb.2004.02.032
  20. Mills K, Johnson A, Winchester B. Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. FEBS Lett 2002;515:171-176. https://doi.org/10.1016/S0014-5793(02)02491-2
  21. Young E, Mills K, Morris P, et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 2005;94:51-54. https://doi.org/10.1080/08035320510028111
  22. Yoon HR, Cho K, Yoo HW, et al. Determination of plasma C16- C24 globotriaosylceramide (Gb3) isoforms by tandem mass spectrometry for diagnosis of Fabry disease. J Genet Med 2007;4:45-52.
  23. Forni S, Fu X, Schiffmann R, Sweetman L. Falsely elevated urinary Gb3(globotriaosylceramide, CTH, GL3). Mol Genet Metab 2009;97:91. https://doi.org/10.1016/j.ymgme.2009.01.011

Cited by

  1. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance vol.51, pp.1, 2010, https://doi.org/10.1136/jmedgenet-2013-101857
  2. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease vol.52, pp.4, 2010, https://doi.org/10.1136/jmedgenet-2014-102872
  3. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype vol.96, pp.29, 2010, https://doi.org/10.1097/md.0000000000007387
  4. Fabry Nephropathy: An Evidence-Based Narrative Review vol.43, pp.2, 2010, https://doi.org/10.1159/000488121
  5. Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995-2019 vol.33, pp.3, 2010, https://doi.org/10.1007/s40620-019-00663-6
  6. Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish co vol.58, pp.10, 2021, https://doi.org/10.1136/jmedgenet-2020-107162
  7. High-Risk Screening for Fabry Disease: A Nationwide Study in Japan and Literature Review vol.11, pp.10, 2021, https://doi.org/10.3390/diagnostics11101779